CD79A and cancer: In addition, we identified other OA risk pathways including inflammatory bowel disease (IBD), human T-cell leukemia virus 1 infection, RA, influenza A, asthma, tuberculosis, prostate cancer, hematopoietic cell lineage, transcriptional misregulation in cancer, allograft rejection, mitogen-activated protein kinase (MAPK) signaling pathway, TH7 cell differentiation, graft-versus-host disease, toxoplasmosis, type 1 diabetes mellitus, cell cycle, intestinal immune network for IgA production, autoimmune thyroid disease, and ubiquitin-mediated proteolysis.